{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:00:33Z","timestamp":1790834433593,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Sarcomas are rare and heterogeneous malignancies for which therapeutic options remain limited, particularly in advanced disease. Standard treatments, including surgery, radiotherapy, chemotherapy, and approved targeted agents, provide marginal improvements in progression-free and overall survival, highlighting the need for immunotherapeutic strategies. Therapeutic cancer vaccines represent a promising strategy, but clinical efficacy has been limited by low antigen immunogenicity and an immunosuppressive tumor microenvironment (TME). Enhancing antigen presentation and T-cell receptor (TCR) engagement through heteroclitic peptide engineering may overcome immune tolerance and improve vaccine efficacy. Preliminary data from our group demonstrate that heteroclitic peptides modified at TCR-facing and anchor residues enhance antigen-specific T-cell recognition, cross-reactivity with wild-type epitopes, and tumor control in preclinical models. In this study, we aim to design and validate optimized heteroclitic epitopes derived from sarcoma-associated TAAs. We developed an integrated computational and experimental workflow to identify and optimize HLA-A*02:01-restricted epitopes derived from sarcoma-associated TAAs. Candidate wild-type (WT) peptides were selected using NetMHCpan 4.1 based on predicted HLA binding affinity and subsequently engineered through systematic amino acid substitutions to generate heteroclitic variants. Optimized peptides were evaluated by structural modeling and molecular docking, followed by experimental\n                    <jats:italic>in vitro<\/jats:italic>\n                    validation using T2-cell HLA stabilization assays. Their immunogenicity was assessed ex vivo in peripheral blood mononuclear cells (PBMCs) isolated from HLA-A*02:01-positive sarcoma patients using IFN-\u03b3 ELISpot and peptide\u2013HLA dextramer analyses. The sequential optimization strategy generated heteroclitic variants with markedly improved predicted HLA-A*02:01 binding for most target proteins. Structural modeling indicated preservation of the peptide backbone and TCR-accessible surface for the majority of selected variants. These predictions were supported experimentally: several heteroclitic peptides enhanced HLA-A*02:01 stabilization and prolonged peptide\u2013MHC complex persistence in T2 cells. Ex vivo, optimized peptides induced stronger antigen-specific IFN-\u03b3 responses than their wild-type counterparts, with significant increases for SET, CAGE, PTPN1 and MAGE-A3, while multimer staining demonstrated recognition of heteroclitic peptide\u2013HLA complexes by wild-type-primed CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. These findings establish a transferable workflow for engineering more immunogenic, yet antigenically faithful, HLA-A*02:01-restricted epitopes. Rational heteroclitic optimization may therefore provide a useful platform for the development of next-generation therapeutic vaccines for sarcoma and other tumors with low intrinsic immunogenicity.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1960095","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:42:24Z","timestamp":1790833344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptide optimization to improve antigen presentation and antitumor responses in sarcoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Angela","family":"Mauriello","sequence":"first","affiliation":[{"name":"Innovative Immunological Models Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Ragone","sequence":"additional","affiliation":[{"name":"Innovative Immunological Models Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Cavalluzzo","sequence":"additional","affiliation":[{"name":"Innovative Immunological Models Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lucia","family":"Tornesello","sequence":"additional","affiliation":[{"name":"Innovative Immunological Models Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Clemente","sequence":"additional","affiliation":[{"name":"Sarcoma and Rare Tumors Medical Oncology Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Picozzi","sequence":"additional","affiliation":[{"name":"Sarcoma and Rare Tumors Medical Oncology Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gallo","sequence":"additional","affiliation":[{"name":"Orthopedic Oncologic Surgery, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[{"name":"Sarcoma and Rare Tumors Medical Oncology Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Buonaguro","sequence":"additional","affiliation":[{"name":"Innovative Immunological Models Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tagliamonte","sequence":"additional","affiliation":[{"name":"Innovative Immunological Models Unit, National Cancer Institute IRCCS - \u201cFond G. Pascale\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","unstructured":"Seer*Stat Database: Incidence\u2014Seer 9 Regs Research Data, November 2010 Sub (1973\u20132008) <Katrina\/Rita Population Adjustment>\u2014Linked to County Attributes\u2014Total U.s. 1969\u20132009 Counties\n          \n          \n          \n          2011"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-2-14","article-title":"The epidemiology of sarcoma","volume":"2","author":"Burningham","year":"2012","journal-title":"Clin Sarcoma Res"},{"key":"B3","volume-title":"Soft Tissue and Bone Tumors, 5th Ed","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103203","DOI":"10.1016\/j.eclinm.2025","article-title":"Genetic predisposition in sarcomas: clinical implications and management","volume":"83","author":"Connolly","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2016.05.005","article-title":"Epidemiology and etiology of sarcomas","volume":"96","author":"Hui","year":"2016","journal-title":"Surg Clinics North America"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6142613","article-title":"Epidemiology of soft tissue sarcoma and bone sarcoma in Italy: Analysis of data from 15 population-based cancer registries","volume":"2020","author":"Fabiano","year":"2020","journal-title":"Sarcoma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000447083","article-title":"Sarcomas of soft tissue and bone","volume":"43","author":"Ferrari","year":"2016","journal-title":"Prog Tumor Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0561-4","article-title":"Systemic therapy for soft tissue sarcoma: Proposals for the optimal use of pazopanib, trabectedin, and eribulin","volume":"34","author":"Kawai","year":"2017","journal-title":"Adv Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3747\/co.27.5475","article-title":"Update on systemic therapy for advanced soft-tissue sarcoma","volume":"27","author":"Smrke","year":"2020","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/948501","article-title":"Human tumor antigens and cancer immunotherapy","volume":"2015","author":"Vigneron","year":"2015","journal-title":"BioMed Res Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: Current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12967-020-02306-y","article-title":"Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy","volume":"18","author":"Raza","year":"2020","journal-title":"J Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ijc.1307","article-title":"MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas","volume":"93","author":"Dalerba","year":"2001","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin Sarcoma Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-065x.2002.18803.x","article-title":"Cancer\/testis antigens: An expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27446","article-title":"NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid\/round cell liposarcoma","volume":"118","author":"Pollack","year":"2012","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2122","article-title":"Knockdown of PRDX2 inhibits the proliferation, growth, migration, invasion, and MMP9 activity of Ewing's sarcoma cells cultured in vitro","volume":"7","author":"Xue","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23199","article-title":"PCAT6 mediates cellular biological functions in gastrointestinal stromal tumor via upregulation of PRDX5 and activation of Wnt pathway","volume":"59","author":"Bai","year":"2020","journal-title":"Mol Carcinog"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-008-0330-4","article-title":"Global protein-expression analysis of bone and soft tissue sarcomas","volume":"466","author":"Kawai","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s41065-025-00588-0","article-title":"DExD-box helicase 39 A, targeted by coumestrol, facilitates the Malignant behaviors of osteosarcoma cells","volume":"162","author":"Haiqing","year":"2025","journal-title":"Hereditas"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1021\/pr400929h","article-title":"Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma","volume":"13","author":"Kubota","year":"2014","journal-title":"J Proteome Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"23084","DOI":"10.1038\/s41598-024-67659-6","article-title":"Deciphering the prognostic and therapeutic significance of BAG1 and BAG2 for predicting distinct survival outcome and effects on liposarcoma","volume":"14","author":"Lian","year":"2024","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cell.2013.02.036","article-title":"Reversible disruption of mSWI\/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma","volume":"153","author":"Kadoch","year":"2013","journal-title":"Cell"},{"key":"B27","article-title":"Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations","volume":"61","author":"Worley","year":"2001","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1634\/theoncologist.2016-0025","article-title":"Immunotherapy: A new (and old) approach to treatment of soft tissue and bone sarcomas","volume":"23","author":"Michael","year":"2018","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3747\/co.27.5407","article-title":"Immunotherapy in soft-tissue sarcoma","volume":"27","author":"Ayodele","year":"2020","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase I trial combining decitabine\/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: Overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.01.005","article-title":"Combinatorial immunotherapy strategies for hepatocellular carcinoma","volume":"39","author":"Tagliamonte","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2019.12.029","article-title":"Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches","volume":"473","author":"Tagliamonte","year":"2020","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1488564","article-title":"Potentiating cancer vaccine efficacy in liver cancer","volume":"7","author":"Tagliamonte","year":"2018","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.973317","article-title":"Antigen-specific vaccines for cancer treatment","volume":"10","author":"Tagliamonte","year":"2014","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.6.2539","article-title":"Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues","volume":"157","author":"Parkhurst","year":"1996","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.3.6.985","article-title":"Design of multi-epitope, analogue-based cancer vaccines","volume":"3","author":"Fikes","year":"2003","journal-title":"Expert Opin Biol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445114","article-title":"Structural basis for ineffective T-cell responses to MHC anchor residue-improved \"heteroclitic\" peptides","volume":"45","author":"Madura","year":"2015","journal-title":"Eur J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41541-025-01118-9","article-title":"Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer","volume":"10","author":"Shah","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12967-021-02757-x","article-title":"Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy","volume":"19","author":"Cavalluzzo","year":"2021","journal-title":"J Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.769799","article-title":"MHC-optimized peptide scaffold for improved antigen presentation and anti-tumor response","volume":"12","author":"Tagliamonte","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002694","article-title":"Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs)","volume":"9","author":"Ragone","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.150.3693.178","article-title":"Automated synthesis of peptides","volume":"150","author":"Merrifield","year":"1965","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1960095\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:42:27Z","timestamp":1790833347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1960095\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1960095"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1960095","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1960095"}}